𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The efficacy and safety of ɛ-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis

✍ Scribed by B. GUNAWAN; B. RUNYON

Book ID
108604383
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
70 KB
Volume
23
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hyperfibrinolysis increases the risk of
Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis
✍ Francesco Violi; Domenico Ferro; Stefania Basili; Claudio Quintarelli; Mirella S 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 597 KB

Sixty-one patients with different degrees of liver failure, 23 with Child-Pugh class B and 38 with Child-Pugh class C, were studied and observed for 3 yr. Coagulation index analysis showed significantly lower values of prothrombin activity, more prolonged activated partial thromboplastin time, highe

Hyperfibrinolysis Resulting from Clottin
Hyperfibrinolysis Resulting from Clotting Activation in Patients with Different Degrees of Cirrhosis
✍ Francesco Violi; Domenico Ferro; Claudio Quintarelli; Antonio Musca; Francesco B 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 628 KB

This study explored the relationship between clotting activation and tissue plasminogen activator and its inhibitor in cirrhotic patients with different degrees of liver failure. Sixty-seven patients (40 men, 27 women; age = 31-77 yr) with cirrhosis diagnosed by liver biopsy were divided into three

Torasemide in the treatment of patients
Torasemide in the treatment of patients with cirrhosis and ascites
✍ Paolo Gentilini; Giacomo Laffi; Giorgio La Villa; Vinicio Carloni; Marco Foschi; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 493 KB

The effects of torasemide (20 mg/day) and furosemide (50 mg/day), each given over 4 days, were compared in a randomized and crossover study carried out in seven patients with cirrhosis and tense ascites. Patients also received a low-sodium (40 mmol/day) diet and the aldosterone antagonist, potassium

Safety and efficacy of 22 weeks of treat
Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria
✍ Phillip Lee; Eileen P. Treacy; Eric Crombez; Melissa Wasserstein; Lewis Waber; J 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract Phenylketonuria (PKU) is an inherited metabolic disease characterized by phenylalanine (Phe) accumulation, which can lead to neurocognitive and neuromotor impairment. Sapropterin dihydrochloride, an FDA‐approved synthetic formulation of tetrahydrobiopterin (6R‐BH4, herein referred to as